Suven Life Sciences to present pre-clinical data of their NCEs at SFN

14 Nov 2011 Evaluate

Suven Life Sciences will be presenting several data presentation from their portfolio of investigational neuroscience new chemical entities (NCEs) at SFN from 13th to 16th of November at Washington, DC, US. Neuroscience is the annual meeting of the Society for Neuroscience (SFN) and more than 30,000 Neuro scientists from all over the world covering all the major Pharma, biotech and research institutes will be participating.

Suven’s nine data presentation covers the early stage compounds from Histamine 3receptor antagonist, Nicotinic acetylcholine alpha- beta-2 receptor agonist and antagonist, Serotonin 5-HT4 receptor against in addition to 5HT6 antagonists to treat unmet medical needs of patients living with cognitive  dysfunction associated with Alzheimer’s, Schizophrenia, ADHD; Depression and Mood disorders and  Neuropathic pain.

These data presentation highlights company’s continued commitment to exploring new treatment  options addressing unmet medical need through novel mechanism and targets and address a market size of more than $30 billon.

Suven Life Sciences Share Price

110.99 -2.20 (-1.94%)
26-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1504.25
Dr. Reddys Lab 6263.70
Cipla 1406.25
Zydus Lifesciences 948.20
Lupin 1615.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.